Abstract: A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Abstract: Systems, methods, and computer-readable media are disclosed for dynamically inserting secondary content into a live stream or a video on demand (VOD). The secondary content can include, for example, a public service announcement or warning, censoring content, live or prerecorded commentary, an advertisement, or any other type of content to be integrated with or inserted into the main content. Example methods may include receiving a content stream including a first fragment having a first duration and a second fragment having the first duration. Certain methods may include determining an increased quality of service associated with encoding the content stream into fragments having a second duration. Certain methods may include generating, based at least in part on the increased quality of service, a third fragment having the second duration, and sending the content stream having the third fragment to a user device.

Abstract: Systems, methods, and computer-readable media are disclosed for dynamically inserting secondary content into a live stream or a video on demand (VOD). The secondary content can include, for example, a public service announcement or warning, censoring content, live or prerecorded commentary, an advertisement, or any other type of content to be integrated with or inserted into the main content. Example methods may include receiving a content stream including a first fragment having a first duration and a second fragment having the first duration. Certain methods may include determining an increased quality of service associated with encoding the content stream into fragments having a second duration. Certain methods may include generating, based at least in part on the increased quality of service, a third fragment having the second duration, and sending the content stream having the third fragment to a user device.

Abstract: A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

Abstract: A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.